NCT05558319: Phase 3: (GEM21menos65) Extended VRD Plus vs Isa-VRD vs Isa-V-Iberdomide - NDMM - ASCT




- Sep 22, 2022
NCT05552976: Phase 3: CC-92480 + Carfilzomib-dex (480Kd) Vs Carfilzomib-dex (Kd) RRMM (SUCCESSOR-2)


- Aug 31, 2022
NCT05519085: Phase 3: CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM -SUCCESSOR-1


- May 11, 2022
NCT05372354: Phase 1/2: CC-92480 (BMS-986348) in Combination With Other Treatments in RRMM Myeloma


- Dec 15, 2021
NCT05064787: Evaluating the Feasibility of a Digital Health Coaching Program Post CART


- Aug 5, 2021
NCT04975997: Phase 3: IberDd Versus DVd in Participants With Relapsed Refractory Myeloma - EXCALIBER


- Aug 5, 2021
NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants RRMM


- Jun 29, 2021
NCT04934475: Phase 3 - IFM 2020-02 Minimal Residual Disease Adapted Strategy (MIDAS) KRD-Isatuximab


- Jun 11, 2021
Expanded Access Protocol for Receiving Idecabtagene Vicleucel That is Nonconforming for commercial


- Jun 9, 2021
NCT04776395: Phase 2: Iberdomide Alone or in Combination With Dex for Intermediate/High-Risk SMM


- May 31, 2021
NCT04855136 : Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)


- Dec 27, 2020
NCT04674813: Phase 1 - A Study of CC-95266 in Subjects With Relapsed and/or Refractory Myeloma


- Dec 18, 2020
NCT04635735: Phase 1/2: Study of Ipilimumab After Stem Cell Transplantation in People With RRMM


- Dec 17, 2020
NCT04555551:Phase 1 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for Multiple Myeloma


- Dec 10, 2020
NCT04287855: Phase 2: Phase 2 Study of Isatuximab + Pomalidomide, Dex, Carfilzomib RRMM -IFM2018-03


- Dec 9, 2020
NCT04564703: EMN26 Phase 2: Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients


- Jul 17, 2020
NCT04392037: Phase 2: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON)

- Jul 10, 2020
NCT04394650: Phase 1 - CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in RRMM


- Dec 27, 2019
NCT04196491: Phase 1 - Evaluate the Safety of bb2121 in High Risk, New Myeloma (NDMM) (KarMMa-4)


- Dec 19, 2019
NCT04036461: Phase 1 - A Study of CC-99712, a BCMA Antibody-Drug Conjugate in relapsed MM


- Dec 13, 2019
NCT04009109: Phase 2 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in TIE NDMM


- Dec 12, 2019
NCT04150965: Phase 1/2: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT


- Dec 11, 2019
NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002


- Dec 6, 2019
NCT04113018: Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dex NDMM


- Dec 31, 2018
NCT03590652: Phase 2 - Daratumumab, Ixazomib, Pomalidomide + Dex as Salvage Therapy Refractory MM


- Dec 23, 2018
NCT03486067: Phase 1 - CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in relapsed Multiple Myeloma


- Dec 19, 2018
NCT03601078: Phase 2 -Efficacy and Safety of bb2121 in relapsed MM & in high risk Myeloma (KarMMa-2)


- Dec 16, 2018
NCT03651128: Phase 3 - Study of bb2121 Vs Standard Regimens Refractory Myeloma (RRMM) (KarMMa-3)


- Dec 13, 2018
NCT03435796: Phase 2/3: Long-Term Follow-up for Participants Treated With Gene-Modified T Cells


- Dec 7, 2018
NCT01554852: Phase 3- Thalidomide, Lenalidomide, Carfilzomib, Bortezomib, Vorinostat-NDMM Myeloma XI


- Dec 6, 2018
NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG)


- Dec 3, 2018
NCT03720041: Phase 3 Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Elig. New MM (FiTNEss)


- Dec 29, 2017
NCT03274219 : Phase 1 - bb21217 an Anti-BCMA CAR T Cell Drug Product, in RRMM - CRB-402


- Dec 15, 2017
NCT03106324: Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma -TNE


- Dec 15, 2017
NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma


- Dec 7, 2017
NCT03030261: Phase 2: Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second ASCT RRMM


- Dec 6, 2017
NCT03188172: Phase 2 - MUK Nine b: OPTIMUM Treatment Protocol (MUKnineb)


- Dec 5, 2017
NCT03361748 : KarMMa - Phase 2 - To Determine the Efficacy and Safety of bb2121 in refractory MM


- Dec 16, 2016
NCT02773030: Phase 1/2: CC-220 Monotherapy and in Combination With Treatments in NDMM / RRMM


- Dec 9, 2016
NCT02655458: Phase 1 - Elotuzumab in Comb. With Auto transplant and Lenalidomide Maintenance in MM


- Dec 9, 2016
NCT02658929: Phase 1 - Study of bb2121 in BCMA-Expressing refractory Multiple Myeloma CRB-401


- Dec 9, 2016
NCT02916771: Phase 2: Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in SMM


- Dec 9, 2016
NCT02886065: Phase 1 - PVX-410, a Cancer Vaccine, & Citarinostat +/- Lenalidomide for Smoldering MM


- Dec 8, 2016
NCT02654132 : Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab ( ELOQUENT-3)


- Dec 7, 2016
NCT02969837: Phase 2 - Study of Initial Treatment With Elotuzumab, Carfilzomib, Len and Dex NDMM


- Dec 3, 2016
NCT02786511: Longterm Follow-up of Subjects Treated With bb2121


- Dec 19, 2015
NCT02415413: Phase 2 - Carfilzomib in Patients Under 65 With High Risk Smoldering MM GEM-CESAR trial


- Dec 18, 2015
NCT02612779: Phase 2 - Elotuzumab in Combination With Pomalidomide and Low dose Dex Vs Nivo/Elo